EUCTR2005-003230-18-GB进行中（未招募）1 期
A prospective double-blind, randomised, cross-over trial to compare the effects of adding buprenorphine or morphine to Transtec for 'breakthrough' pain in patients with severe pain due to osteoarthritis of hip or knee. - Transtec in OA pain
Barts and The London NHS Trust0 个研究点目标入组 50 人开始时间: 2005年9月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Subjects older than 40 years of age.
- •2. Subjects who have given their written informed consent.
- •3. At baseline, female subjects of childbearing potential must be using adequate contraception (i.e. using oral or IM contraception or an IUCD) and must have a negative urine pregnancy test.
- •4. Subjects with severe OA pain of the hip or knee, whose pain has not been adequately controlled with weak opioids, with or without paracetamol. Severe pain is defined as a clinic pain score of 6 or more on an 11-point Numerical Rating Scale (0=no pain, 10=worst pain imaginable) at screening.
- •5. Subjects who have required analgesic therapy, for at least 60 out of the last 90 days.
- •At randomisation:
- •Patients must have required an average of at least one 0.2mg Temgesic tablet per day over the last patch administration period in order to be randomised.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects who have previously failed on Transtec therapy.
- •2. Subjects who have received treatment with a potent opioid in the four weeks preceding study entry.
- •3. Subjects who are breastfeeding.
- •4. Contraindications to Transtec, Temgesic or Sevredol as listed in their respective Summary of Product Characteristics texts.
- •5. Subjects with documented or suspected alcohol or drug abuse, or who are suspected of having an addictive personality.
- •6. Subjects with a significant psychiatric disorder (including depression) or subects receiving anti-psychotic medication.
- •7. Subjects who are experiencing another type of continuous pain that stands out in comparison with OA pain (e.g. fibromyalgia) and may compromise their target joint pain assessments.
- •8. Subjects to who any of the following applies:
- •- major trauma to the target joint in the six months preceding study entry
- •- infection in the target joint in the six months preceding study entry
- •- apparent avascular necrosis in the target joint in the six months preceding study entry
- •- intra-articular injections of corticosteroids in the target joint in the two months preceding study entry, or hyalorunan injections in the target joint in the six months preceding study entry
- •- subjects who have started any form of physiotherapy, massage or physical therapy, transcutaneous electrical nerve stimulation (TENS) in the three weeks preceding study entry. Such therapies can continue if they were started more thsn three weeks before the start of the study and if they continue at the same frequency of administration throughout the study.
- •9. Subjects for whom a treatment is planned within the study period that could alter the degree or nature of pain.
- •10. Current history of functional disorder of the following systems: gastrointestinal, renal, hepatic, respiratory, cardiovascular, central nervous system. likely to adversely affect the patient's participation in the study.
- •11. Subjects wo have received an investiagtional drug or have used an investigational device in the 30 days preceding study entry.
- •12. Subjects unable to comply with the study assessments or complete the questionnaires.
- •13. Subjects who have previously been admitted to this study.
研究者
相似试验
进行中（未招募）
不适用
A prospective, randomised, double-blind crossover study comparing 0.15 g/L rhBSSL added to infant formula versus placebo during one week of treatment in preterm infants born before week 32 of gestational age - BVT.BSSL-020Enzyme replacement therapy in pre-term infants. Reduced fad uptake capabilities due to prematurity of pre-term infantsMedDRA version: 9.1Level: HLGTClassification code 10013317Term: Lipid metabolism disordersEUCTR2007-002423-33-ITBIOVITRUM AB32
进行中（未招募）
不适用
A prospective, randomised, double-blind crossover study comparing 0.15 g/L rhBSSL added to pasteurized breast milk versus placebo during one week of treatment in preterm infants born before week 32 of gestational age - NDEUCTR2007-002434-10-ITBIOVITRUM AB32
进行中（未招募）
1 期
A prospective, randomised, double-blind crossover study comparing 0.15 g/L rhBSSL added to pasteurized breast milk versus placebo during one week of treatment in preterm infants born before week 32 of gestational age - BVT. BSSL - 021Enzyme replacement therapy in pre-term infants. Reduced fat uptake capabilities due to prematurity of pre-term infantsEUCTR2007-002434-10-FRBiovitrum AB (publ.)32
已完成
3 期
Clinical trial on paraxanthine (PX) in comparison to that of caffeine (CF) in otherwise healthy volunteersCTRI/2022/03/041219Ingenious Ingredients24
招募中
不适用
A randomized, double-blind, two-way cross-over study to determine the effects of levetiracetam on corticospinal excitability in patients with treatment-controlled epilepsy, as measured by single and paired pulse TMS-EMG and TMS-EEG10039911EpilepsyNL-OMON49353Centre for Human Drug Research32